Cite
HARVARD Citation
Faleck, D. et al. (n.d.). DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis. Journal of Crohn's and colitis. p. S066. [Online].